Clinical Trials Logo
  1. Home
  2. Influenza
  3. NCT05087355
  4. Details
NCT05087355 Clinical Trial

Health Status Prior and Post Infection With Influenza or COVID 19: a Population Based Retrospective Analysis of 2016-2021

Influenza Clinical Trial

Official title:
Health Status Prior and Post Infection With Influenza or COVID 19: a Population Based Retrospective Analysis of 2016-2021

Clinical Trial Details — Status: Completed

Administrative data
NCT number NCT05087355
Other study ID # AUTCOV-INFLU-STUDY
Secondary ID
Status Completed
Phase
First received
Last updated
Start date January 1, 2016
Est. completion date August 31, 2021

Study information
Verified date October 2021
Source Medical University of Vienna
Contact n/a
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

The overall project aim is to study outcomes after COVID-19 and influenza hospitalisation from 2016 - 2021 by retrieving data from the main social security carriers in Austria for the years 2010-2018

Recruitment information / eligibility
Status Completed
Enrollment 440000
Est. completion date August 31, 2021
Est. primary completion date August 31, 2021
Accepts healthy volunteers No
Gender All
Age group N/A and older
Eligibility Inclusion Criteria: - Patients with SARS - Patients with Covid-19 - Patients after Covid-19 - Patients with influenza Exclusion Criteria: - none

Study Design

Related Conditions & MeSH terms

Intervention

Diagnostic Test:
• PCR or antigen test for Covid 19 or Inluenza
PCR or antigen test for Covid 19 or Inluenza

Locations
Country Name City State
n/a

Sponsors (4)
Lead Sponsor Collaborator
Medical University of Vienna A.ö. Krankenhaus St. Josef Braunau GmbH, Landesklinikum Sankt Polten, Sicknessfund Burgenland (BGKK)

Outcome
Type Measure Description Time frame Safety issue
Primary Overall Mortality Overall mortality after influenza or covid-19 5 years
Primary age distribution age distribution in patients with influenza or covid-19 5 years
Primary risk profile risk profile (e.g. prior diseases, medication) in patients who died due to influenza or covid-19 5 years
Primary newly diagnosed diseases newly diagnosed diseases after influenza or covid-19 5 years
Primary newly prescribed medication newly prescribed medication after influenza or covid-19 5 years
Primary duration of hospitalisation or unemployability duration of hospitalisation or unemployability after influenza or covid-19 5 years
See also
  Status Clinical Trial Phase
Completed NCT05523089 - The Effectiveness of CD388 to Prevent Flu in an Influenza Challenge Model in Healthy Adults Phase 2
Completed NCT05009251 - Using Explainable AI Risk Predictions to Nudge Influenza Vaccine Uptake N/A
Completed NCT03282240 - Safety and Immunogenicity of High-Dose Quadrivalent Influenza Vaccine in Participants ≥65 Years in the US Phase 3
Completed NCT00968526 - Study to Evaluate Immunogenicity and Safety of an Investigational Influenza Vaccine (H1N1) in Adults Phase 3
Completed NCT00971425 - Evaluation of the Immune Response and the Safety of a Pandemic Influenza Candidate Vaccine (H1N1) Phase 3
Completed NCT00968539 - Study to Evaluate the Immunogenicity & Safety of an Investigational Influenza Vaccine (H1N1) in Adults Phase 3
Completed NCT05525494 - Patient Portal Flu Vaccine Reminders (5) N/A
Completed NCT04074928 - Safety and Immunogenicity Study of QIVc in Healthy Pediatric Subjects Phase 3
Completed NCT04695717 - This Study Was Conducted to Evaluate the Safety and Immunogenicity of IVACFLU-S Produced in Children From 6 Months to Under 18 Years Old and the Elderly Over 60 Years Old in Vietnam Phase 3
Completed NCT05012163 - Lottery Incentive Nudges to Increase Influenza Vaccinations N/A
Completed NCT03888989 - Response to Influenza Vaccine During Pregnancy Phase 1
Completed NCT04109222 - Collection of Serum Samples From Children and Older Adults Receiving the 2019-2020 Formulations of Fluzone® Quadrivalent and Fluzone® High-Dose Influenza Vaccines, Respectively Phase 4
Completed NCT02587221 - Clinical Study to Evaluate the Efficacy, Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Influenza Vaccine Compared to Non-influenza Vaccine Comparator in Adults ≥ 65 Years of Age Phase 3
Completed NCT03453801 - The Role of CD4+ Memory Phenotype, Memory, and Effector T Cells in Vaccination and Infection Phase 1
Completed NCT01440387 - A Study of Immunogenicity and Safety of GSK Biologicals' Influenza Vaccine FLU-Q-QIV in Adults Aged 18 Years and Older Phase 3
Terminated NCT01195779 - Trial to Evaluate Safety and Immunogenicity of GSK Biologicals' Influenza Vaccine GSK2584786A in Healthy Children Phase 2
Completed NCT03321968 - Lot-to-lot Consistency of a Plant-Derived Quadrivalent Virus-Like Particles Influenza Vaccine in Healthy Adults Phase 3
Completed NCT00972517 - Study to Evaluate the Immunogenicity and Safety of an Investigational Influenza Vaccine (H1N1) in Children Phase 3
Completed NCT04570904 - Broadening Our Understanding of Early Versus Late Influenza Vaccine Effectiveness
Recruiting NCT03331991 - Prevention of Influenza and Other Wintertime Respiratory Viruses Among Healthcare Professionals in Israel N/A